Perspective Therapeutics (CATX) Invested Capital (2022 - 2026)

Perspective Therapeutics has disclosed Invested Capital across 5 years of filings, most recently posting $325.5 million for Q2 2026.

• In Q2 2026, Invested Capital rose 21.74% year-over-year to $325.5 million; the TTM figure through Jun 2026 stood at $325.5 million (up 21.74% YoY), while the FY2025 annual figure was $208.7 million, down 28.63% from the prior year.
• Invested Capital came in at $325.5 million for Q2 2026 at Perspective Therapeutics, down from $349.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $349.0 million in Q1 2026 to a low of $54.6 million in Q4 2022.
• Average Invested Capital over 5 years is $222.7 million, with a median of $243.9 million recorded in 2025.
• Year-over-year, Invested Capital jumped 280.14% in 2024 and retreated 28.63% in 2025.
• Over 5 years, Invested Capital stood at $54.6 million in 2022, then soared by 40.74% to $76.9 million in 2023, then jumped by 280.14% to $292.3 million in 2024, then retreated by 28.63% to $208.7 million in 2025, then surged by 55.98% to $325.5 million in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were $325.5 million in Q2 2026, $349.0 million in Q1 2026, and $208.7 million in Q4 2025.